Study Details

Back to Search Results

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT04079296

Astellas Study ID

The unique identification code given by the study sponsor.

7517-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Leukemia - AML, Bone Marrow Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - N/A

Sex

Female & Male

Product

ASP7517

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2019 - Jun 2023

Masking

None (Open Label)

Enrollment number

43

A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP81004

Maebashi, Japan

Site JP81007

Kobe, Japan

Site JP81008

Okayama, Japan

Site JP81005

Nagoya, Japan

Site JP81001

Shinagawa, Japan

Site JP81002

Fukuoka, Japan

Site JP81009

Yoshida-gun, Japan

Site JP81010

Gifu, Japan

Site JP81011

Osaka, Japan

Site JP81013

Isehara, Japan

Site JP81012

Osaka, Japan

Site JP81016

Matsuyama, Japan

Site JP81014

Bunkyo, Japan

Gabrail Cancer Center

Canton, United States, 44718

Memorial Healthcare System-West

Pembroke Pines, United States, 33028

City of Hope

Duarte, United States, 91010

Site JP81017

Sendai, Japan

Site JP81015

Yokohama, Japan

University of Chicago Comprehensive Cancer Center

Chicago, United States, 60637

NYU Langone Health

New York, United States, 10016

Northside Hospital Cancer Institute

Atlanta, United States, 30342

MD Anderson Cancer Center

Houston, United States, 77030

UAB O’Neal Comprehensive Cancer Center

Birmingham, United States, 35233

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo